Key takeaways
- • VA covers select GLP-1s through the VA National Formulary, dispensed by VA pharmacies, not retail — verify current criteria.
- • T2D agents (Ozempic, Mounjaro, Rybelsus) may be considered when PBM criteria-for-use and step-therapy are documented.
- • Wegovy/Zepbound for weight management require BMI thresholds, comorbidity, prior failure, and a structured program like MOVE!.
- • VA is exempt from the Medicare Part D weight-loss exclusion but applies its own stricter cost-stewardship criteria.
- • Compounded GLP-1s are not FDA-approved as finished products and are not provided through the VA pharmacy system.
How VA (Veterans Affairs / Veterans Health Administration) approaches GLP-1 coverage
The Veterans Health Administration provides GLP-1 receptor agonists through the VA National Formulary (VANF) and dispenses them via VA pharmacies rather than retail. Coverage is governed by VA Pharmacy Benefits Management (PBM) criteria-for-use documents, which are typically more restrictive than commercial payer policies due to federal cost-stewardship and Federal Supply Schedule pricing. As of 2025, semaglutide (Ozempic) and tirzepatide (Mounjaro) may be considered for type 2 diabetes when documented criteria are met, while Wegovy and Zepbound for chronic weight management generally require BMI thresholds, documented prior intervention failure, and enrollment in a structured weight-management pathway such as MOVE!. VA prescribers must often try preferred or older agents first; non-criteria-use requests require a formal exception. Veterans should verify all specifics with their VA primary care team, VA pharmacy, and the current VANF criteria-for-use document for the specific medication and indication.
Statutory and structural notes
VA pharmacy benefits operate under 38 U.S.C. §1710 and §1722A and are administered through the VA National Formulary established under 38 U.S.C. §8126 (Federal Supply Schedule pricing). VA is NOT subject to Medicare Part D's statutory weight-loss exclusion (MMA 2003, SSA §1860D-2(e)(2)(A)) because it is a separate federal benefit, not a Part D plan. Coverage criteria are set by VA PBM, not CMS, and may differ materially from Medicare or commercial rules.
Typically considered for coverage
The list below reflects general patterns observed across VA (Veterans Affairs / Veterans Health Administration)plan documents. Coverage for any specific drug, dose, or indication must be confirmed against your own plan's current formulary and medical policy.
- Semaglutide (Ozempic) for type 2 diabetes when VA PBM criteria-for-use are met; may be considered for coverage; verify with your specific plan and current formulary.
- Tirzepatide (Mounjaro) for type 2 diabetes when criteria-for-use are met and step-therapy with preferred agents is documented; may be considered for coverage; verify with your specific plan and current formulary.
- Semaglutide (Wegovy) for chronic weight management when BMI, comorbidity, and prior intervention criteria are met and the veteran is engaged in a structured weight-management program; may be considered for coverage; verify with your specific plan and current formulary.
- Tirzepatide (Zepbound) for chronic weight management or its FDA-approved obstructive sleep apnea indication when VA criteria-for-use are met; may be considered for coverage; verify with your specific plan and current formulary.
- Oral semaglutide (Rybelsus) for type 2 diabetes when criteria are met; may be considered for coverage; verify with your specific plan and current formulary.
Typically excluded
- Compounded semaglutide and tirzepatide products — not FDA-approved as finished drug products and not dispensed through VA pharmacies.
- GLP-1s prescribed without documented qualifying indication (e.g., cosmetic weight loss, BMI below threshold).
- Prescriptions written by non-VA providers and filled outside VA pharmacy channels without Community Care authorization.
- Branded products when a therapeutically equivalent VA-preferred agent has not been tried first, absent an approved exception.
- Off-label use not supported by VA PBM criteria-for-use guidance.
Prior authorization
Prior authorization is commonly required for GLP-1 medications under VA (Veterans Affairs / Veterans Health Administration) plans. Your prescriber typically submits a PA form with diagnosis codes, lab results (e.g., A1c for T2D, BMI for weight management), documented prior therapy attempts, and clinical justification.
Appeal strategy if denied
If denied, the VA prescriber can submit a non-formulary or non-criteria-use request through VA PBM with clinical justification (labs, BMI history, comorbidities, prior therapy failures). Veterans may also file a clinical appeal via the VA Patient Advocate, request a Clinical Appeals review, or escalate through VHA Office of Community Care. Verify current appeal pathways with your VA facility.
GLP1Zoom is not an insurance company, broker, or health plan. We summarize general payer patterns from public plan documents and statute to help you ask the right questions. Always verify current coverage with your plan's member services. Full disclaimer.